Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-09-25

Gossamer Bio (GOSS)

CEO Faheem Hasnain was paid $2,300,455 in fiscal year 2025, ↑ up 14.7% from fiscal year 2024, the 24th percentile of its disclosed peer group (SEC filing 0001728117-26-000027 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,300,455 ↑
Faheem Hasnain total, FY2025
24th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
93.65%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

GOSS's next annual pay disclosure, estimated April 19, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Faheem Hasnain$649,649$0$0$1,392,006$254,800$0$4,000$2,300,455
Chairman, President and Chief Executive Officer
Bryan Giraudo519,83000576,688152,91304,0001,253,431
Chief Operating Officer and Chief Financial Officer
Robert Smith463,50075,0000517,031121,21304,0001,180,744
Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Faheem Hasnain$2,300,455$2,005,432$2,095,988↑ +295,023
Bryan Giraudo1,253,4311,171,9041,287,882↑ +81,527
Robert Smith1,180,744———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Gossamer Bio's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper GOSS reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against GOSS
10 companies name GOSS as a compensation peer

The list of companies that name GOSS as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Faheem HasnainCEO$2,300,455
Bryan GiraudoCFO$1,253,431
Robert SmithCCO$1,180,744
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
John Quisel, Ph.D., J.DIndependent Director$172,069
Russell CoxIndependent Director$186,319
Sandra Milligan, M.D., J.DIndependent Director$179,319
Skye DrynanIndependent Director$181,444
Steven Nathan, M.DIndependent Director$167,444
Thomas Daniel, M.DLead Independent Director$199,569
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Steven D. NathanDirector2026-06-04A115,000$0$0Derivative, Class A CommonForm 4 ↗
Sandra MilliganDirector2026-06-04A115,00000Derivative, Class A CommonForm 4 ↗
Russell CoxDirector2026-06-04A115,00000Derivative, Class A CommonForm 4 ↗
Thomas O. DanielDirector2026-06-04A115,00000Derivative, Class A CommonForm 4 ↗
Skye DrynanDirector2026-06-04A115,00000Derivative, Class A CommonForm 4 ↗
John D. QuiselDirector2026-06-04A115,00000Derivative, Class A CommonForm 4 ↗
Faheem HasnainDirector2026-08-24A5,800,05100Derivative, Class A CommonForm 4 ↗
Bryan GiraudoCOO/CFO2026-08-24A5,800,05100Derivative, Class A CommonForm 4 ↗
Caryn PetersonChief Development Officer2026-08-24A5,800,05100Derivative, Class A CommonForm 4 ↗
Waage ChristianEVP, Tech Ops and Admin2026-08-24A2,900,02600Derivative, Class A CommonForm 4 ↗
Bryan GiraudoCOO/CFO2026-08-24A251,00025,000Derivative, Class A CommonForm 4 ↗
Robert SmithChief Commercial Officer2026-08-24A5,800,05100Derivative, Class A CommonForm 4 ↗
Faheem HasnainDirector2026-08-24A1661,000166,000Derivative, Class A CommonForm 4 ↗
Steven D. NathanDirector2026-09-23A10,00000Derivative, Class A CommonForm 4 ↗
Russell CoxDirector2026-09-23A10,00000Derivative, Class A CommonForm 4 ↗
John D. QuiselDirector2026-09-23A10,00000Derivative, Class A CommonForm 4 ↗
Skye DrynanDirector2026-09-23A10,00000Derivative, Class A CommonForm 4 ↗
Gregory Austin CiongoliDirector2026-09-23A30,00000Derivative, Class A CommonForm 4 ↗
Thomas O. DanielDirector2026-09-23A10,00000Derivative, Class A CommonForm 4 ↗
Sandra MilliganDirector2026-09-23A10,00000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Faheem HasnainOPTION—————$1,392,006
Bryan GiraudoOPTION—————576,688
Robert SmithOPTION—————517,031
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Faheem Hasnain$0$0$1,392,0060.0%
Bryan Giraudo00576,6880.0%
Robert Smith00517,0310.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Bryan GiraudoOption638,0001.13—
Robert SmithPSU162,500—503,750
Faheem HasnainOption683,5940.97—
Bryan GiraudoOption66,0941.21—
Faheem HasnainOption1,540,0001.13—
Faheem HasnainOption209,6360.84—
Faheem HasnainOption170,1571.21—
Bryan GiraudoOption283,2040.97—
Faheem HasnainPSU437,500—1,356,250
Robert SmithOption750,0000.97—
Bryan GiraudoPSU181,250—561,875
Faheem HasnainOption750,0001.36—
Bryan GiraudoOption86,8500.84—
Robert SmithOption572,0001.13—
Robert SmithOption487,5000.97—
05

Incentive-plan design — the Compensation Discussion & Analysis

The key objectives of our executive compensation program are: To attract, engage and retain an executive team who will provide leadership for our future success by providing competitive total pay opportunities. To establish a direct link between our business results, individual executive performance and total executive compensation. To align the interests of our named executive officers with those of our stockholders.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantAlpine Rewards
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-04111,286,5507,545,502137,46193.65%Passed
20252025-06-25125,358,4853,769,651472,93097.08%Passed
20242024-06-06115,985,18240,356,9195,831,13374.19%Passed
20232023-06-0838,901,35519,975,93187,31666.07%Passed
20222022-06-0946,093,471345,87631,93099.26%Passed
20212021-06-0950,886,375298,5412,688,85799.42%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0493.65%a
20252025-06-2597.08%b
20242024-06-0674.19%c

a. Approved under the standard stated in the filing — “Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal.”.

b. Approved under the standard stated in the filing — “Abstentions are not an affirmative or negative vote on a proposal, so abstaining does not count as a vote cast and has no effect for purposes of determining whether our stockholders have ratified the appointment of Ernst & Young LLP, our independent registered public accounting firm, whether our stockholders have approved the compensation of the named executive officers, or whether our stockholders have approved the amendment and restatement our 2019 Incentive Award Plan.”.

c. Approved under the standard stated in the filing — “Abstentions are not an affirmative or negative vote on a proposal, so abstaining does not count as a vote cast and has no effect for purposes of determining whether our stockholders have ratified the appointment of Ernst & Young LLP, our independent registered public accounting firm, or whether our stockholders have approved the compensation of the named executive officers.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Thomas Daniel, M.DIndependent · Lead Independent Director · Compensation · Nominating/Governance$76,875$0$122,694—$0$199,569
Russell CoxIndependent · Audit · Compensation (Chair)63,6250122,694—0186,319
Skye DrynanIndependent · Audit (Chair)58,7500122,694—0181,444
Sandra Milligan, M.D., J.DIndependent · Compensation · Nominating/Governance (Chair)56,6250122,694—0179,319
John Quisel, Ph.D., J.DIndependent · Audit49,3750122,694—0172,069
Steven Nathan, M.DIndependent · Nominating/Governance44,7500122,694—0167,444
Faheem HasnainEmployee director · Board Chair000—00
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 12,000 / 8,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$350,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$350,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Gossamer Bio names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Gossamer Bio.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1RAPT Therapeutics2024Brian Wong$630,000$0$5,927,297$416,000$6,979,539
2Allakos2023Robert Alexander805,4602,171,3402,623,519684,6416,299,426
3Allogene Therapeutics2025David Chang724,0002,409,5372,588,329400,0106,136,093
4AnaptysBio2025Daniel Faga706,0111,592,0013,345,653465,9686,133,943
5Mineralys Therapeutics2025Jon Congleton636,50004,435,626472,6015,544,727
6Erasca2025Jonathan Lim670,40003,135,250482,6884,298,838
7Trevi Therapeutics2025Jennifer Good622,38202,968,26003,944,892
8Poseida Therapeutics2023Mark Gergen611,6671,442,2851,413,936336,4203,818,018
9Annexon2025Douglas Love670,83302,522,260371,2503,579,202
10aTyr Pharma2025Sanjay Shukla638,97702,595,200210,8623,456,253
11Atea Pharmaceuticals2025Jean-Pierre Sommadossi703,4901,315,800962,368422,0943,403,752
12Fulcrum Therapeutics2025Alex Sapir650,00002,052,132411,2003,251,490
13Kodiak Sciences2025Victor Perlroth792,4970923,032772,8242,499,221
14Gossamer Bio2025Faheem Hasnain649,64901,392,006254,8002,300,455
15Alector2025Arnon Rosenthal678,100422,876558,216325,4881,995,018
16Mersana Therapeutics2024Michael Huber632,500133,635518,044322,5751,613,754
17Zentalis Pharmaceuticals2025Julie Eastland700,00099,77256,975441,0001,300,731
18Ventyx Biosciences2024Raju Mohan621,9200303,800342,0451,283,015

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Gossamer Bio65%not disclosedNoAlpine Rewards
Alector80%not disclosednot disclosedPearl Meyer & Partners, LLC
Allakosnot disclosedOptions 55 · RSU 45NoCompensia
Allogene Therapeuticsnot disclosedOption 55 · RSU 25 · PSU 20not disclosedCompensia
AnaptysBio110%not disclosedNoAlpine Rewards
Annexon100% of target%not disclosednot disclosedAlpine Rewards
Atea Pharmaceuticalsnot disclosednot disclosednot disclosedAon
aTyr Pharma60% (Committee lowered payout from 75% achievement to 60% given EFZO-FIT study results)%Option 100not disclosedRadford
Erasca120%Options 100not disclosedAlpine Rewards, LLC
Fulcrum Therapeuticsnot disclosedOption 100not disclosedAon
Kodiak Sciences150%Options 100not disclosedCompensia, Inc.
Mersana Therapeuticsnot disclosedOption 75 · RSU 25not disclosedPearl Meyer & Partners, LLC
Mineralys Therapeuticsnot disclosedOption 100not disclosednot disclosed
Poseida Therapeuticsnot disclosednot disclosednot disclosedAon Consulting, Inc.
RAPT Therapeutics120%Option 100not disclosedAon plc/Radford
Trevi Therapeuticsnot disclosednot disclosednot disclosednot disclosed
Ventyx Biosciencesnot disclosednot disclosednot disclosedAON/Radford
Zentalis Pharmaceuticals105%not disclosednot disclosedAnderson Pay Advisors LLC / Pay Governance LLC

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Gossamer Bio in fiscal 2025?
As disclosed, Faheem Hasnain (Chairman, President and Chief Executive Officer) was the highest-paid executive at Gossamer Bio in fiscal 2025, with total compensation of $2,300,455.
How does Gossamer Bio's chief executive pay compare to its disclosed peer group?
As disclosed, Faheem Hasnain's total compensation ranked at the 24th percentile of Gossamer Bio's disclosed peer group.
How did shareholders vote on Gossamer Bio's executive compensation?
As disclosed, 93.65% of shareholders supported Gossamer Bio's executive compensation in the latest say-on-pay vote.
How much does Gossamer Bio spend in total on board compensation for fiscal 2025?
As disclosed, Gossamer Bio reported total board compensation of $350,000 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Faheem HasnainDEF 14A2026-04-240001728117-26-000027Section “Summary Compensation Table”. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568
2Section 01, Bryan GiraudoDEF 14A2026-04-240001728117-26-000027Section “Summary Compensation Table”. As printed: 1,253,431. Filing ↗machine: r5 · c48 · span 385546–385555
3Section 01, Robert SmithDEF 14A2026-04-240001728117-26-000027Section “Summary Compensation Table”. As printed: 1,180,744. Filing ↗machine: span 392612–392621
4Section 03, Faheem Hasnain OPTIONDEF 14A2026-04-240001728117-26-000027Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r2 · c13 · span 377176–377185
5Section 03, Bryan Giraudo OPTIONDEF 14A2026-04-240001728117-26-000027Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r5 · c13 · span 384546–384553
6Section 03, Robert Smith OPTIONDEF 14A2026-04-240001728117-26-000027Section “OUR EXECUTIVE COMPENSATION BEST PRACTICES &” · grants of plan-based awards table. Filing ↗machine: t22 · r8 · c13 · span 391387–391394
7Section 07, pay ratio10-K2026-03-170001728117-26-000017Section “CEO Pay Ratio”. As printed: —. Filing ↗
8Section 08, Thomas Daniel, M.DDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 199,569. Filing ↗machine: t11 · r5 · c11 · span 195847–196153
9Section 08, Russell CoxDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 186,319. Filing ↗machine: t11 · r4 · c11 · span 193956–194262
10Section 08, Skye DrynanDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 181,444. Filing ↗machine: t11 · r3 · c11 · span 192148–192404
11Section 08, Sandra Milligan, M.D., J.DDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 179,319. Filing ↗machine: t11 · r6 · c10 · span 197449–197666
12Section 08, John Quisel, Ph.D., J.DDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 172,069. Filing ↗machine: t11 · r7 · c10 · span 199184–199426
13Section 08, Steven Nathan, M.DDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 167,444. Filing ↗machine: t11 · r2 · c11 · span 190463–190795
14Section 08, Faheem HasnainDEF 14A2026-04-240001728117-26-000027Section “Director Compensation”. As printed: 0. Filing ↗
15Section 02, Steven D. Nathan 2026-06-04Form 42026-06-050002015114-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Sandra Milligan 2026-06-04Form 42026-06-050001859810-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Russell Cox 2026-06-04Form 42026-06-050001512984-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Thomas O. Daniel 2026-06-04Form 42026-06-050001538894-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Skye Drynan 2026-06-04Form 42026-06-050002015102-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, John D. Quisel 2026-06-04Form 42026-06-050001728117-26-000047Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Faheem Hasnain 2026-08-24Form 42026-08-260001352620-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Bryan Giraudo 2026-08-24Form 42026-08-260001740847-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Caryn Peterson 2026-08-24Form 42026-08-260001857256-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Waage Christian 2026-08-24Form 42026-08-260001553179-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Bryan Giraudo 2026-08-24Form 42026-08-260001740847-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Robert Smith 2026-08-24Form 42026-08-260002003059-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Faheem Hasnain 2026-08-24Form 42026-08-260001352620-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Steven D. Nathan 2026-09-23Form 42026-09-250001628280-26-063593Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Russell Cox 2026-09-23Form 42026-09-250001628280-26-063601Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, John D. Quisel 2026-09-23Form 42026-09-250001628280-26-063606Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Skye Drynan 2026-09-23Form 42026-09-250001628280-26-063610Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Gregory Austin Ciongoli 2026-09-23Form 42026-09-250001628280-26-063616Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Thomas O. Daniel 2026-09-23Form 42026-09-250001628280-26-063619Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Sandra Milligan 2026-09-23Form 42026-09-250001628280-26-063624Insider equity transaction reported since the proxy statement. Filing ↗
35Section 06, 2026 voteForm 8-K2026-06-050001728117-26-000042Item 5.07 · say-on-pay result. As reported: 93.65% (votes for as printed: 111,286,550). Filing ↗
36Section 06, 2025 voteForm 8-K2025-06-250001728117-25-000043Item 5.07 · say-on-pay result. As reported: 97.08% (votes for as printed: 125,358,485). Filing ↗
37Section 06, 2024 voteForm 8-K2024-06-100001728117-24-000069Item 5.07 · say-on-pay result. As reported: 74.19% (votes for as printed: 115,985,182). Filing ↗
38Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
39Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
40Section 09b board cost (computed)Computed——Cash 350,000 + equity 0 + all other 0 = 350,000, summed across the director compensation table rows.machine: formula: Σ = 350,000
41RAPT Therapeutics, Section 10b CEO totalDEF 14A2025-04-140000950170-25-053517CEO total compensation as printed in RAPT Therapeutics's own proxy. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861
42Allakos, Section 10b CEO totalDEF 14A2024-04-230000950170-24-047043CEO total compensation as printed in Allakos's own proxy. As printed: 6,299,426. Filing ↗machine: r2 · c26 · span 505098–505107
43Allogene Therapeutics, Section 10b CEO totalDEF 14A2026-04-300001628280-26-028948CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023
44AnaptysBio, Section 10b CEO totalDEF 14A2026-06-290001193125-26-288408CEO total compensation as printed in AnaptysBio's own proxy. As printed: 6,133,943. Filing ↗machine: span 694406–694415
45Mineralys Therapeutics, Section 10b CEO totalDEF 14A2026-04-080001933414-26-000069CEO total compensation as printed in Mineralys Therapeutics's own proxy. As printed: 5,544,727. Filing ↗machine: r2 · c48 · span 235758–235767
46Erasca, Section 10b CEO totalDEF 14A2026-04-280001193125-26-187361CEO total compensation as printed in Erasca's own proxy. As printed: 4,298,838. Filing ↗machine: r2 · c31 · span 221524–221533
47Trevi Therapeutics, Section 10b CEO totalDEF 14A2026-04-210001193125-26-166695CEO total compensation as printed in Trevi Therapeutics's own proxy. As printed: 3,944,892. Filing ↗machine: r2 · c21 · span 594331–594340
48Poseida Therapeutics, Section 10b CEO totalDEF 14A2024-04-250000950170-24-048291CEO total compensation as printed in Poseida Therapeutics's own proxy. As printed: 3,818,018. Filing ↗machine: span 428155–428164
49Annexon, Section 10b CEO totalDEF 14A2026-04-270001140361-26-017085CEO total compensation as printed in Annexon's own proxy. As printed: 3,579,202. Filing ↗machine: r2 · c24 · span 356205–356214
50aTyr Pharma, Section 10b CEO totalDEF 14A2026-03-260001339970-26-000021CEO total compensation as printed in aTyr Pharma's own proxy. As printed: 3,456,253. Filing ↗machine: r2 · c21 · span 533754–533763
51Atea Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-270001193125-26-182293CEO total compensation as printed in Atea Pharmaceuticals's own proxy. As printed: 3,403,752. Filing ↗machine: r3 · c22 · span 1526943–1526952
52Fulcrum Therapeutics, Section 10b CEO totalDEF 14A2026-04-300001193125-26-197196CEO total compensation as printed in Fulcrum Therapeutics's own proxy. As printed: 3,251,490. Filing ↗machine: r2 · c25 · span 336588–336597
53Kodiak Sciences, Section 10b CEO totalDEF 14A2026-04-220001193125-26-170429CEO total compensation as printed in Kodiak Sciences's own proxy. As printed: 2,499,221. Filing ↗machine: r4 · c14 · span 905058–905068
54Gossamer Bio (subject), Section 10b CEO totalDEF 14A2026-04-240001728117-26-000027CEO total compensation as printed in Gossamer Bio's own proxy. As printed: 2,300,455. Filing ↗machine: r2 · c48 · span 378559–378568
55Alector, Section 10b CEO totalDEF 14A2026-04-280001193125-26-186928CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674
56Mersana Therapeutics, Section 10b CEO totalDEF 14A2025-04-290001104659-25-040448CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. Filing ↗machine: r1 · c41 · span 608188–608197
57Zentalis Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-300001725160-26-000027CEO total compensation as printed in Zentalis Pharmaceuticals's own proxy. As printed: 1,300,731. Filing ↗machine: r2 · c48 · span 319348–319357
58Ventyx Biosciences, Section 10b CEO totalDEF 14A2025-04-230000950170-25-057384CEO total compensation as printed in Ventyx Biosciences's own proxy. As printed: 1,283,015. Filing ↗machine: r2 · c25 · span 569480–569489
59Section 10a, Zentalis Pharmaceuticals reciprocityDEF 14A—0001725160-23-000078Zentalis Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
60Section 10a, Allogene Therapeutics reciprocityDEF 14A—0001628280-26-028948Allogene Therapeutics's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
61Section 10a, Atea Pharmaceuticals reciprocityDEF 14A—0001193125-26-182293Atea Pharmaceuticals names Gossamer Bio in its own disclosed peer group (read from its most recent proxy). Filing ↗
62Section 10a, Alector reciprocityDEF 14A—0001193125-26-186928Alector's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
63Section 10a, aTyr Pharma reciprocityDEF 14A—0001339970-26-000021aTyr Pharma names Gossamer Bio in its own disclosed peer group (read from its most recent proxy). Filing ↗
64Section 10a, Trevi Therapeutics reciprocityDEF 14A—0001193125-26-166695Trevi Therapeutics's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
65Section 10a, Kodiak Sciences reciprocityDEF 14A—0001193125-26-170429Kodiak Sciences's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
66Section 10a, Allakos reciprocityDEF 14A—0000950170-24-047043Allakos's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
67Section 10a, Mersana Therapeutics reciprocityDEF 14A—0001104659-25-040448Mersana Therapeutics's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗
68Section 10a, AnaptysBio reciprocityDEF 14A—0001193125-26-288408AnaptysBio's most recent proxy was read; its disclosed peer group does not include Gossamer Bio. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.